StreetAlpha.app
Home › Stocks › XGN

Exagen Inc. (XGN)

$3.61
▼ −5.00%
LAST CLOSE · NOV 20

Exagen makes AVISE brand blood tests that help doctors diagnose autoimmune and related rheumatic diseases. It last closed at $3.61 on Nov 20, down 5.00% on the day. The next earnings report for XGN is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, XGN reported EPS of -$0.25 on revenue of $18.4M, with revenue up 6.8% from a year ago. Over its last 8 reports the stock moved an average of 17.0% the session after earnings. Over the last 12 months XGN insiders bought $569K of stock on the open market and sold $1.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is XGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold XGN.

Key Stats

Last 12 months
Results
Revenue
$72.3M
+13.7% vs a year ago
Net income
−$18.2M
−25.1% margin
EPS (diluted)
−$0.76
Free cash flow
−$13.0M
−18.0% margin
Valuation
Market cap
$92.1M
25.5M shares
P/E
–
No P/E while losing money
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$28.1M
At Sep 30
Debt
$22.8M
At Sep 30
Shareholder equity
$13.8M
Shares outstanding
25.5M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $48.3M$48.3MFY2021FY2022: $45.6M$45.6MFY2022FY2023: $52.5M$52.5MFY2023FY2024: $55.6M$55.6MFY2024FY2025: $66.6M$66.6MFY2025

From XGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.25
Quarter ended Sep 2026
Year ago EPS
-$0.31
Same quarter last year
Revenue
$18.4M
+6.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.20Dec '24Mar 2025: -$0.20Mar '25Jun 2025: -$0.21Jun '25Sep 2025: -$0.31Sep '25Dec 2025: -$0.20Dec '25Mar 2026: -$0.17Mar '26Jun 2026: -$0.13Jun '26Sep 2026: -$0.25Sep '26Latest -$0.25
Revenue by quarter
Dec 2024: $13.7MDec '24Mar 2025: $15.5MMar '25Jun 2025: $17.2MJun '25Sep 2025: $17.2MSep '25Dec 2025: $16.6MDec '25Mar 2026: $17.3MMar '26Jun 2026: $19.9MJun '26Sep 2026: $18.4MSep '26Latest $18.4M
How XGN moved after its last 8 reports
Average move the session after a report ±17.0%
Nov 10, 2026Time not announced−25.9%
Aug 4, 2026Time not announced+37.8%
May 11, 2026Time not announced+34.9%
Mar 10, 2026Time not announced−3.9%
Jan 12, 2026Time not announced−6.2%
Nov 4, 2025Time not announced−9.0%
Jul 29, 2025Time not announced+14.3%
May 5, 2025Time not announced+3.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on XGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on XGN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on XGN

Technical Analysis

XGN · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 72% below its 20 day and 104% below its 50 day average. It is 42% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the Pivot S1 at $3.43, and the nearest resistance the Pivot at $3.66.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 18.8%/day
Key levels
$9.2252 week high+155.4%
$7.3650 day average+103.9%
$6.67100 day average+84.8%
$6.2220 day average+72.3%
$5.13200 day average+42.1%
$4.85Swing high (Jun 15)+34.3%
$3.85Pivot R1+6.6%
$3.66Pivot+1.4%
$3.61Last close
$3.43Pivot S1−5.0%
$2.5952 week low−28.3%
Indicators
RSI (14)27.45Oversold below 30Oversold
MACD-1.15Below its signal lineBearish
Stochastic4.6Near the bottom of its rangeOversold
ADX (14)38.9Trending down
Williams %R-97.5Oversold below −80, overbought above −20Oversold
CCI (20)-96.0Oversold below −100, overbought above 100Neutral
Rate of change−37.9%Change over 10 sessionsBearish
ATR (14)$0.68Typical daily range, 18.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XGN

What happened before

See how XGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow XGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How XGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for XGNHow many large options trades hit XGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

XGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲53 buying vs 21 selling
  • ▲Held by funds +8.5 pts
  • ▲Funds holding +21
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7857+36.8%
In funds' top 10220.0%
Held by funds40.9%32.4%+8.5 pts
New / increased26 / 278 / 15+130.4%
Reduced / sold out16 / 524 / 12−41.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

XGN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$569K3 buys · 1 insider
Sold$1.3M7 sales · 3 insiders
2026-02 sold $47K2026-03 sold $57K2026-09 sold $149K2026-10 bought $104K2026-10 sold $270K2026-11 bought $464K2026-11 sold $815KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 13Jorey Chernett10% ownerSale167,504$4.45$746K
Nov 11Jorey Chernett10% ownerBuy71,315$5.23$373K
Nov 10Jorey Chernett10% ownerBuy15,585$5.85$91K
Nov 6Jorey Chernett10% ownerSale11,265$6.14$69K
Oct 19Jorey Chernett10% ownerBuy14,000$7.46$104K
Oct 16John AballiPresident and CEOSale34,294$7.87$270K
Every insider buy and sale for XGN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See XGN insider trades →

From SEC Form 4 filings by XGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XGN is in one of them and how their past XGN trades turned out.

XGN in the AI portfolios
Loading…

XGN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XGN in an article yet. Here's the latest on the wider market.

XGN in the news

About Exagen

Exagen is a medical technology company based in Vista, California, that makes diagnostic tests for autoimmune and related rheumatic diseases. Its main product line, sold under the AVISE brand, includes AVISE CTD, which helps clinicians tell apart conditions with overlapping symptoms, such as lupus and rheumatoid arthritis. Its tests are used mainly by rheumatologists, with primary care physicians, other specialists, hospitals and healthcare systems also among its customers. The company runs its own clinical laboratory to process the tests.

Headquarters
Vista, CA
Founded
2002